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Summary Several animal studies have shown that both the epilepsy itself and many
antiepileptic drugs (AEDs) affect reproductive endocrine function in both males and
females. Epileptic activity may lead to arrested ovarian cyclicity, anovulatory cycles,
polycystic ovaries, and endocrine changes in female animals. In males, seizures
disturb normal reproductive physiology by inducing endocrine changes, alterations
in gonadal size, and hyposexuality. Several AEDs also affect endocrine function,
fertility, and gonadal morphology in both sexes. This paper reviews the literature
regarding animal studies related to reproductive disorders in epilepsy. Although care
should always be taken when applying data from animal experiments to the human
situation, animal models provide a unique possibility for investigating the indepen-
dent effects of the epilepsy itself and the effects of AEDs in isolation, without
confounding factors. By constantly comparing results from clinical and animal studies,
and by developing appropriate animal models, several mechanistic questions regard-
ing the complex interplay between epilepsy, hormones, and AEDs can be explored.
Animal experiments should play an integral part in the study of reproductive endo-
crine disorders in epilepsy.




Reproductive endocrine dysfunction is unusually
common among women and men with epilepsy.1 In
women, menstrual disorders, polycystic ovaries,
and infertility have been described,1—3 while in
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oi:10.1016/j.seizure.2007.11.008have been found.1,4,5 In both sexes, sexual pro-
blems6 and endocrine changes are frequently
described.1,2,3
The reasons for the changes in reproductive
endocrine function are multifactorial, including
both the epilepsy itself and the antiepileptic med-
ication. In addition, confounding factors like loss of
self-confidence, social rejection, and other psycho-
social problems may affect endocrine function and
reproductive health.
Animal studies allow us to investigate the inde-
pendent effects of the epilepsy itself and the effects. Published by Elsevier Ltd. All rights reserved.
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confounding factors. The effects of the individual
drugs can be studied at different doses and time
intervals, and possible cellular and genetic mechan-
isms of action of the different drugs can be studied
in detail.Reproductive endocrine effects of
epilepsy
It is well known that epilepsy itself affects the secre-
tion of pituitary hormones.1,7 Even the laterality of
epileptic activity may be of importance as left-sided
temporal foci seem to increase the occurrence of
polycystic ovaries in women, while right-sided foci
increase the frequency of hypogonadotropic hypogo-
nadism.8
In a series of experiments, Edwards et al.9,10
showed how seizures affected reproductive function
in both female and male rats. In females, amygdala-
kindled seizures arrested ovarian cyclicity in all
animals. The animals also had high serum estradiol,
increased pituitary weight, and polyfollicular ovar-
ies consisting of many cystic follicles, as well as
follicles in various stages of growth and atresia.
Progesterone treatment of kindled females resulted
in a different endocrine profile than that in non-
progesterone-treated, kindled rats with higher
serum estradiol, testosterone, and prolactin levels.
The animals had an increase in pituitary weight,
polycystic ovaries, and thecal cell hyperplasia.
Further, bilateral ablations of the basolateral por-
tion of the amygdala in adult female deer mice can
induce anovulatory cycles and polycystic ovaries.11
Stimulation of the corticomedial amygdala can
induce ovulation and uterine contractions in several
species,12,13 while bilateral amygdalectomy in
female monkeys induces amenorrhea and hypogo-
nadal vaginal changes.14
Electroconvulsive seizures have been shown to
delay the onset of puberty, to attenuate the respon-
siveness of luteinising hormone (LH) and follicle-
stimulating hormone (FSH) to gonadal feedback,
and to increase prolactin release in female rats.15
In male rats, amygdala-kindled seizures resulted
in an increase in serum testosterone, estradiol, and
prolactin in intact males, accompanied by a signifi-
cant increase in testis, epididymis, and pituitary
weight, as well as a significant decrease in prostate
weight.9 Maximal electroshock seizures (MES) treat-
ment caused a short-term reduction in serum tes-
tosterone and a decrease in testis, epididymis, and
prostate weight. These results indicate that both
focal limbic (amygdaloid) seizures and generalized
MES seizures disturb normal reproductive physiologyin the male rat. In cats, it has been shown that
epileptic activity in the temporal lobe induces hypo-
sexuality.16 Bilateral amygdalectomy in both adult
male rats and cats results in marked degeneration of
the testes.17Reproductive endocrine effects of
AEDs
Animal studies on the effect of AEDs on reproduction
can be divided into studies on fertility, semen qual-
ity, gonadal morphology, and endocrinology. Due to
the wide variation in study design, dosage regimens,
and length of treatment, some studies may show
apparently conflicting results. Here we outline some
of the main trends in animal research on this topic,
with particular focus on those long-term studies
which would be of greatest relevance and interest
to clinical practice.
Fertility
It has been claimed that fertility rates have been
reduced after long-term treatment with different
AEDs. In one study, fertility rates in rats after 60
days low-dose drug treatment with either carbama-
zepine (CBZ) or valproate (VPA) was reduced from
90% in controls to 40% and 30%, respectively.18 An
effect of VPA on fertility rates was also observed by
Cohn et al.,19 in a study in which the fertility rates of
young male rats was investigated after 3-months of
treatment with phenytoin (PHT), clonazepam
(CZP), VPA, or CBZ. A significantly reduced fertility
rate was only seen for VPA. The VPA dose used was
30 mg/(kg day), compared with 20 mg/kg for PHT
and CBZ, and 1.8 mg/kg for CZP, but apparently
serum concentrations were not measured. In con-
trast, another study reported that treatingmale rats
with VPA doses of up to 500 mg/kg for 10 weeks had
no effect on the number of pregnancies achieved.20
However, it should be noted that fertility rate itself
is a weak indicator of toxicity on male reproductive
organs.21 Direct measures of female animal fertility
after AED treatment have not been studied in detail.
Fertility is dependent on sexual activity, a regular
oestrus cycle or mating season, and on semen qual-
ity. Very few studies have addressed the issue of
sexual activity in animals after AED treatment, but
doses of VPA of up to 500 mg/(kg day) for 10 weeks
did not seem to reduce copulation in rats.20 Soliman
and Abla Abd,18 however, reported that sexual
desire was reduced in rats treated with either
CBZ or VPA at very low doses.
Little information is available about possible
associations between AEDs and oestrous cycle irre-
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female Wistar rats treated with daily doses CBZ of 5,
10, or 100 mg/kg for 21 days,22 nor has any effect of
VPA on cycle regularity been observed in rats or
monkeys.23,24 However, for both these latter stu-
dies, it is uncertain whether the drug concentrations
were within the therapeutic range for a sufficient
period of time to induce clinically relevant effects.
Due to the much higher metabolic rate for the drug
in these animals, it is probable that the VPA con-
centrations were well below the therapeutic range
for most of the day, and this is one of the major
problems of all animal studies investigating endo-
crine effects of AEDs.
Semen quality
A wide range of so-called ‘‘old’’ AEDs have been
claimed to reduce semen quality in a series of
different animal studies.18,19,20,25,26 The lack of
negative effects on semen quality presently
reported for ‘‘new’’ drugs does not imply that they
have been proven to be without such effects, but
merely reflects the lack of relevant data obtained to
date. In animal studies on the effects of AEDs on
semen quality, which havemostly been performed in
rats, the study duration is very important. It has
been shown that a 4-week drug treatment period is
necessary to examine effects of AEDs on fertility in
rats,27 and in order to include a complete sperma-
togenetic cycle in the rat, which is 50—60 days, a 60-
day treatment period should be used as a mini-
mum.28
Two studies on rats have shown a reduction in
total sperm count, varying from 20% to 40%, after
long-term treatment with CBZ, possibly related to
different dosing regimens.18,19 CZP treatment of
rats also significantly reduced total sperm count.19
It is, however, important to note that in the same
study neither CZP nor CBZ reduced the fertility rate
of the rats.
Considerable interest has been directed towards
the possible effects of VPA on semen quality, which
has been found to be reduced after long-term treat-
ment in mice and rats.18,19,20,25 Both the total
number of sperm and the number of motile sperm
have been found to be significantly reduced in
several different animal studies.18,19,20,25 Addition-
ally, an increase in the number of morphologically
abnormal spermatozoa has been recorded, with an
increase in sperm tail abnormalities.18
To study the effects of VPA in another species, we
recently conducted a study using male goats as the
animal model.26 Nine bucks, aged 2 months at the
start of the study, received VPA mixture twice daily
for 8 months. Serum concentrations of VPA 2 h after
last dose were about 700 mmol/l, after 4 h about500 mmol/l, and after 6 h about 300 mmol/l. A sig-
nificantly higher proportion of sperm from VPA-trea-
ted bucks showed abnormal chromatin, as compared
with controls, demonstrating an adverse effect of
VPA treatment on DNA. Both semen volume, total
sperm count, and sperm motility tended to be lower
in the VPA-treatment group, as compared with con-
trols, but the differences were not significant,
which was probably because of the relatively low
number of animals included in the study.
Effects of AEDs on gonadal morphology
Testis and male accessory sex glands
In one of the very few studies comparing the effects
of different AEDs on gonadal morphology, male rats
were fed with PHT (20 mg/kg), CZP (1.8 mg/kg),
VPA (30 mg/kg), or CBZ (20 mg/kg) daily for 3
months.19 No changes in testicular weight were
observed in any of the study groups. There was,
however, a significant decrease in prostate weight in
the rat groups treated with VPA or CBZ, while VPA
treatment was also associated with a reduction in
epididymis weight. The latter finding was further
reflected in reduced sperm content and motility.19
Most interest regarding the effect of AEDs on
testicular morphology has revolved round VPA.
Chronic toxicity studies from the 1970s, performed
by Abbott laboratories, apparently indicated testi-
cular damage, including degeneration of the inter-
stitial cells after VPA treatment.29 In an early study
byWalker et al.,30 13-week VPA treatment of rats, at
1200 and 1600 mg/(kg day), resulted in testicular
atrophy. In dogs treated for 13 weeks, testicular
atrophy was seen at 400 mg/kg, while mild focal
atrophy also occurred at 100 and 200 mg/kg.30 The
major VPA-induced pathologic lesions were bilateral
testicular atrophy, with reduced or absent sperma-
togenesis, and secondary atrophy of the prostate
and epididymis. As only minor changes were
observed in other organs, it was concluded that
the testes should be considered a target organ for
VPA toxicity. These results are consistent with those
of other studies, which have shown reduced sper-
matogenesis and testicular atrophy of dogs at VPA
doses greater than 90 mg/kg.31 The findings from
Walker et al.30 are supported by some results from
the study of Nishimura et al.,20 which demonstrated
reduced testicular weight and reduced weights of
epididymis, seminal vesicles, and prostate after
long-term VPA treatment of rats.
The effects of long-term VPA treatment on tes-
ticular morphology have been studied in detail in
rats.32 Male Wistar rats were fed perorally twice
daily for 90 days with either VPA (200 or 400 mg/kg),
or lamotrigine (LTG) (5 mg/kg). The main finding
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with a 51% reduction in testicular weight, in the VPA
high-dose treatment group of animals, with no
changes in the other treatment groups. Widespread
testicular atrophy, with histologically verified sper-
matogenetic arrest, was recorded in the VP high-
dose treatment group, but changes were not
observed in the interstitium, including the Leydig
cells. Furthermore, no significant changes in the
testis were seen either in the low-dose VPA-treat-
ment group, or in the LTG-treatment group. No
changes were detected in the liver, heart, lungs,
lymphatic nodes, pancreas, kidney, or brain, which
supports the observations of Walker et al.30 of the
testis being a target organ for VPA toxicity. The
difference in effect between VPA and LTG also
indicates a drug-specific effect of VPA, independent
of epileptic activity, since all the animals used were
healthy, non-epileptic rats.
Effects of AEDs on ovarian morphology
A drug-specific effect of AEDs on ovarian morphol-
ogy has been studied in detail only for VPA, insti-
gated by the ongoing discussions regarding
development of polycystic ovaries following VPA
treatment in female epilepsy patients.
In the study of Snyder and Badura,25 chronic VPA
administration in female rats for 8 weeks led to a
significant reduction in uterine weight after 4 and 6,
but not 8 weeks of age. In the ovary, VPA was
associated with a significant reduction in both fol-
licles and corpora lutea after 6 weeks of age. Again,
no significant changes were observed after 8 weeks
of age. In the same study, humerus length was also
measured, and demonstrated reduced growth after
4 and 6, but not 8, weeks of age. Considering these
results together, the effects of VPA on gonadal and
skeletal growth indicated that pubertal maturation
had been slowed, but not completely halted.
Long-term VPA treatment of adult rats has been
shown to induce an increase in the number of cystic
formations in the ovary. In the study of Taubøll
et al.,33 rats were fed perorally with either control
solution, or VPA (50 or 200 mg/kg) once daily for 90
days,34 resulting in mean serum VPA concentrations
of 72 mmol/l in low-dose treated animals and
200 mmol/l in high-dose treated animals 4 h after
the last dose. In the high-dose group, additional
serum VPA concentration measurements 2, 4, 6,
and 24 h after the last dose were 999, 200, 157,
and 3 mmol/l, respectively. The main finding of this
study was a significant, dose-dependent increase in
the number of cystic formations in the ovaries.
In a second study, female Wistar rats were fed
perorally with either 200 or 300 mg/kg VPA, or 5 mg/kg LTG, or control solution twice daily, for 90 days.34
After a dose of 200 mg/kg VPA, mean serum con-
centrations of VPA were 1444, 819, and 241 mmol/l
after 2, 4, and 6 h. Corresponding values after
300 mg/kg were 1742, 967, and 330 mmol/l. After
12 h, serum concentrations had reduced to 3 mmol/
l. Mean serum concentration of LTG 6 h after last
dose was 38.6 mmol/l. Again, a significant, dose-
dependent increase in the number of follicular cysts
in the ovaries was observed after VPA treatment.
This finding was strengthened by a concomitant
reduction in the number of corpora lutea. No effects
were observed after LTG treatment. A detailed
analysis of a series of other tissues, including liver,
kidney, pancreas, lymphatic tissue, heart, brain,
and cerebellum did not reveal any changes. The
study therefore showed that the effect of VPA was
drug-specific, independent of epileptic activity, and
that the ovaries were a possible target organ.34 This
is further supported by the observations from
another study23 which demonstrated that VPA treat-
ment of rats, at a total dose of 300 mg/(kg day) for
30 days, resulted in an increase in the number of
cystic follicles in the ovary.
However, in contrast, in another study in which a
different animal model, the Rhesus monkey, was
used, 12—15months of VPA treatment did not induce
any discernible changes in ovarian morphology.24
Endocrine effects and possible
mechanisms of action of AEDs on sex
steroid hormones
Several AEDs have been shown to exert a direct
effect on sex steroid hormone production. The first
study in animals to address this question was pub-
lished in 1990, and investigated the effects of VPA,
CBZ, and PHT on different steps of testosterone
biosynthesis in isolated rat Leydig cells.35 Using
sub-maximally stimulating concentrations of human
chorionic gonadotropin (hCG), resulting in physio-
logical testosterone secretion rates, half-maximal
inhibition of testosterone formation occurred in the
presence of 15 mM CBZ, 180 mM PHT, or 900 mM VPA.
Only the values for CBZ were in the clinically ther-
apeutic range. CBZ acted primarily at a target
between cyclic AMP formation and cholesterol con-
version to androgens, while PHT acted by competi-
tive interaction at the cytochrome P450XVIII, which
converts progesterone to androgens.
Some, but not all, benzodiazepines alter andro-
gen production. This may be due to selective effects
of the different benzodiazepines on different types
of benzodiazepine receptors. Peripheral-type ben-
zodiazepine receptors have been characterized in
various tissues, including the ovary and testis. CZP,
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receptors, failed to affect androgen production,
whereas diazepam, which binds to both central
and peripheral benzodiazepine receptors, was able
to induce a significant increment of basal and hCG-
stimulated testosterone production.36 However,
other studies have found that chronic treatment
of male rats with diazepam, administered intraper-
itoneally, is associated with lowered serum testos-
terone levels.37 As there was no difference in serum
LH and FSH, or in the hypothalamic luteinising-
hormone releasing hormone (LHRH) content, it
was suggested that diazepam could act directly
on the testicular interstitial cells to reduce testos-
terone production.37 This theory is supported by
data demonstrating that the peripheral-type ben-
zodiazepine receptor agonist Ro 5-4864 affects
androgen production from suspensions of isolated
rat interstitial cells, suggesting that benzodiaze-
pines acting on peripheral benzodiazepine recep-
tors have a direct effect on Leydig cells.36
Long-term VPA treatment in female rats has been
shown to increase the testosterone to estrogen ratio
markedly, mainly by decreasing estrogen levels.38
With respect to the gonadotropins, there was no
increase in LH after VPA treatment, but there was a
trend towards reduced LH levels at high VPA doses,
which reached statistical significance at the
400 mg/(kg day) dose. No change was seen in FSH
levels. LTG, however, did not affect the hormones
studied. Taken together, these results following
long-term VPA treatment, of a pronounced reduc-
tion in estrogen, a marked increase in the testos-
terone to estrogen ratio, and only minor effects, if
any, on gonadotrophins, might suggest a direct
effect of VPA on peripheral sex steroid hormone
production in the ovary.
In order to investigate the possibility of a direct
effect of VPA on follicular steroidogenesis in more
detail, the secretion of testosterone and estradiol
from isolated porcine ovarian follicles was stu-
died.39 Using concentrations from approximately
600—1500 mmol/l VPA, it was shown that VPA
increased testosterone and reduced estradiol secre-
tion, and reduced the conversion of testosterone to
estradiol. These observations indicate a direct
effect of valproate VPA on steroidogenesis in the
ovary.
A direct effect of VPA has been further supported
by the findings of Hattori et al.,40 with respect to the
presence of the enzyme microsomal epoxide hydro-
lase (mEH) in human ovaries. mEH is important in
detoxification of several substances, and several
studies have shown that VPA inhibits mEH activity.41
Hattori et al.40 demonstrated that human granulosa
cells expressed mEH, and that the inhibition of mEHsuppressed conversion of testosterone to estradiol.
With VPA as a mEH inhibitor, this may be a pathway
by which VPA reduces estrogen levels, and thereby
increases the testosterone to estrogen ratio. This
will lead to an androgen-dominant microenviron-
ment in the ovary, and thereby possibly result in
polycystic changes occurring without an increase in
LH levels.40
Again, however, the study by Ferin et al. using
Rhesus monkeys24 suggests an absence of endocrine
effects associated with long-term treatment with
VPA. However, only seven animals were included in
this study, and there was a trend toward increased
testosterone to estrogen ratio, lower estrogen
levels, and increased LH/FSH ratio. In addition,
body weight was significantly increased.
The possible direct effects of other AEDs, espe-
cially the ‘‘newer’’ ones, should also be studied.
Levetiracetam (LEV) is of particular interest as it
binds to the synaptic vesicle protein SV2A.42 SV2A is
widely distributed in the nervous system and also in
endocrine tissue. If LEV binds to SV2Avesicle protein
in the ovary and/or in the pituitary gland or
hypothalamus, this may provide a link between
the drug and endocrine function at either a central
or peripheral level. In a recent paper, we showed for
the first time that LEV may affect basal, but not
gonadotropin-stimulated, testosterone and estro-
gen secretion from porcine ovarian follicular cells.43
The clinical consequence of this may be that this
AED could be an alternative therapy for women of
fertile age since they will have gonadotropins pre-
sent, and that further studies of LEV are necessary,
especially in young girls with low gonadotropin
levels. It must be emphasised that our finding should
be confirmed in further studies before any definite
conclusions on the clinical relevance of this obser-
vation can be drawn.
Recently, two papers have indicated possible
endocrine effects of topiramate (TPM). In female
rats, treatment with TPM (100 mg/kg) for 12 weeks
reduced fertility and ovarian weight.44 In male rats,
the same dose given for 8 weeks reduced sperma-
togenesis, sperm motility, and the weight of repro-
ductive organs.45 The serum concentrations of TPM
were not measured, and the clinical relevance of
the observations is uncertain. However, these stu-
dies do underline the importance of investigating all
AEDs more closely with regard to possible endocrine
effects.
AEDs may, of course, also influence sex steroid
hormones via a centrally mediated effect, by alter-
ing gonadotropin secretion. A male rat study38
demonstrated a dose-dependent increase in LH
after long-term VPA treatment and also an increase
in FSH at the highest dose. In isolation, this finding
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nervous system. However, the increased gonadotro-
pin levels might also be considered as a compensa-
tory mechanism, related to the marked peripherally
induced effects seen in the animals with testicular
atrophy and spermatogenetic arrest, and unaltered
testosterone levels despite a threefold increase in
LH. Lack of a centrally mediated effect is further
supported by the finding of unchanged FSH and
prolactin levels in mice after 8 weeks of VPA treat-
ment at doses that led to reduced pubertal matura-
tion and alterations in ovarian and testicular
function.25 In contrast, long-term VPA treatment
in rats has been shown to delay gonadotropin-
releasing hormone (GnRH) cell morphological
maturation within the hypothalamus in young, but
not adult, mice.46 Long-term, low-dose, VPA or CBZ
treatment in rats has also been shown to increase
prolactin levels, and to reduce FSH and LH levels, in
male rats.18 A centrally mediated effect of AEDs on
sex hormone regulation can therefore not be
excluded and should be explored in further studies.Concluding remarks–—animal studies
Several animal studies have shown that both the
epilepsy itself, and many AEDs, affect reproductive
endocrine function in both males and females.
Although care should always be taken when applying
data from animal experiments to the human situa-
tion, animal models provide a unique possibility to
investigate the independent effects of the epilepsy
itself, and the effects of AEDs in isolation, without
confounding factors. By constantly comparing results
from clinical and animal studies, and by developing
appropriate animal models, several mechanistic
questions regarding the complex interplay between
epilepsy, hormones, and AEDs can be explored.References
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